PhysEmp :: Medicine :: Medical Specialties :: Hematology (7)

All Hematology-Oncology Jobs

Permanent Hematology-Oncology Job in Call For More Information North Carolina with Medical Search International
A busy hospital located in a beautiful community near Greensboro, NC is seeking a BC/BE Hem/Onc. State license eligibility is acceptable. Fellows are welcomed!! Excellent support staff and coverage.
Permanent Hematology-Oncology Job in ONC 111640 California with Hematology/Oncology - 1 hr to Bay Area
Northern California Hematology/Oncology One hour to the Bay Area 1 year partnership track and buy-in available 1:4 to 1:5 call shared with local Oncologists Practice 25% Hematology and 75% Oncology
Locum to Permanent Hematology-Oncology Job in Call For More Information Indiana with Medical Search International
This client wants someone that can join the group and really make a difference. They do have Chemo on site and they see a wide range of patients. There is a great support staff here and you will always

Current Opinion in Hematology - Current Table Of Contents

Editorial introductions.
Page: viiDOI: 10.1097/MOH.0b013e32830c9354
Current management of thrombotic thrombocytopenic purpura.
Page: 445DOI: 10.1097/MOH.0b013e328309ec62Authors: Kremer Hovinga, Johanna A; Meyer, Sara C
Current management of acquired factor VIII inhibitors.
Page: 451DOI: 10.1097/MOH.0b013e328309ecabAuthors: Barnett, Brian; Kruse-Jarres, Rebecca; Leissinger, Cindy A

Hematological Oncology

Molecular targeting of the PKC-[beta] inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression
Donata Verdelli, Lucia Nobili, Katia Todoerti, Daniela Intini, Maria Cosenza, Monica Civallero, Jessika Bertacchini, Giorgio Lambertenghi Deliliers, Stefano Sacchi, Luigia Lombardi, Antonino Neri Mon, 01 Sep 2008 03:59:00 -0000
The protein kinase C (PKC) pathway has been shown to play a role in the regulation of cell proliferation in several haematological malignancies, including multiple myeloma (MM). Recent data have shown that a PKC inhibitor, enzastaurin, has antiproliferative and proapoptotic activity in a large panel of human myeloma cell lines (HMCLs). In order to further characterise the effect of enzastaurin in MM, we performed gene expression profiling of enzastaurin-treated KMS-26 cell line. We identified 62 upregulated and 32 downregulated genes that are mainly involved in cellular adhesion (CXCL12, CXCR4), apoptosis (CTSB, TRAF5, BCL2L1), cell proliferation (IGF1, GADD45A, BCMA (B-cell maturation antigen), CDC20), transcription regulation (MYC, MX11, IRF4), immune and defence responses. Subsequent validation by Western blotting of selected genes in four enzastaurin-treated HMCLs was consistent with our microarray analysis. Our data indicate that enzastaurin may affect important processes involved in the proliferation and survival of malignant plasma cells as well as in their interactions with the bone marrow microenvironment and provide a preclinical rationale for the potential role of this drug in the treatment of MM. Copyright © 2008 John Wiley & Sons, Ltd.
A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma
TE Sondergaard, PT Pedersen, TL Andersen, K Søe, T Lund, B Østergaard, P Garnero, J-M Delaisse, T Plesner Thu, 31 Jul 2008 04:00:00 -0000
Several studies have evaluated the impact of low dose statin (20-80 mg/day) on bone metabolism with inconclusive results despite promising data of preclinical studies. In this study, we investigated the effect of high dose simvastatin (HD-Sim) on biochemical markers of bone turnover and disease activity in six heavily pretreated patients with multiple myeloma (MM). These patients were treated with simvastatin (15 mg/kg/day) for 7 days followed by a rest period of 21 days in two 4-week cycles. Endpoints were changes in the level of biochemical markers of (i) osteoclast activity (tartrate resistant acid phosphatase, TRACP); (ii) bone resorption (collagen fragments CTX and NTX); (iii) bone formation (osteocalcin and aminoterminal propeptide of type I collagen PINP); (iv) cholesterol; (v) regulators of bone metabolism [osteoprotegerin (OPG) and Dickkopf-1 (DKK-1)] and (vi) disease activity (monoclonal proteins or free light chains in serum). TRACP activity in serum and levels of collagen fragments (NTX) in urine increased for all patients temporarily during the 7 days of treatment with HD-Sim indicating that osteoclasts may have been stimulated rather than inhibited. The other markers of bone metabolism showed no change. None of the patients showed any reduction in free monoclonal light chains or monoclonal proteins in serum during treatment with HD-Sim. In spite of the fact that bone turn over effects of HD-Sim may have been blunted by concomitant treatment of patients with other drugs we observed a transient increase in markers of osteoclast activity. This sign of a transient stimulation of osteoclast activity suggests that HD-Sim may be harmful rather than beneficial for MM patients. For this reason and because of gastro-intestinal side effects the study was stopped prematurely. Copyright © 2008 John Wiley & Sons, Ltd.
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study
JE Chang, PM Voorhees, JM Kolesar, HG Ahuja, FA Sanchez, GA Rodriguez, K Kim, J Werndli, HH Bailey, BS Kahl Thu, 31 Jul 2008 04:00:00 -0000
Arsenic trioxide (As2O3) has established clinical activity in acute promyelocytic leukaemia and has pre-clinical data suggesting activity in lymphoid malignancies. Cell death from As2O3 may be the result of oxidative stress. Agents which deplete intracellular glutathione, such as ascorbic acid (AA), may potentiate arsenic-mediated apoptosis. This multi-institution phase II study investigated a novel dosing schedule of As2O3 and AA in patients with relapsed or refractory lymphoid malignancies. Patients received As2O3 0.25 mg/kg IV and AA 1000 mg IV for five consecutive days during the first week of each cycle followed by twice weekly infusions during weeks 2-6. Cycles were repeated every 8 weeks. The primary end point was objective response. In a subset of patients, sequential levels of intracellular glutathione and measures of Bcl-2 and Bax gene expression were evaluated in peripheral blood mononuclear cells during treatment. Seventeen patients were enrolled between March 2002 and February 2004. The median age was 71, and the majority of enrolled patients had non-Hodgkin's lymphoma (12/17). Sixteen patients were evaluable, and one patient with mantle cell lymphoma achieved an unconfirmed complete response after five cycles of therapy for an overall response rate of 6%. The trial, which had been designed as a two-stage study, was closed after the first stage analysis due to lack of activity. Haematologic toxicities were the most commonly reported events in this heavily pre-treated population, and comprised the majority of grade 3 and 4 toxicities. Intracellular depletion of glutathione was not consistently observed during treatment. As2O3 and AA in this novel dosing strategy was generally well tolerated but had limited activity in patients with relapsed and refractory lymphoid malignancies. Copyright © 2008 John Wiley & Sons, Ltd.

Annals of Hematology

Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation
Thu, 04 Sep 2008 06:41:41 -0000
Abstract  Pure red cell aplasia (PRCA) is a well-known, although infrequent, hematological complication after allogeneic hematopoietic stem cell transplantation (HSCT). PRCA occurs in cases of major ABO mismatch between donor and recipient and is believed to be due to inhibition of donor erythroid progenitors by residual host isohemagglutinins. The purpose of our study was to further evaluate the efficacy of human adipose tissue-derived mesenchymal stem cells (AMSC) as the salvage therapy for refractory PRCA after major ABO-incompatible HSCT. Two patients with refractory pure red cell aplasia received intravenous infusions of AMSC at a dose of 1.5 × 106/kg of the patients’ weight, and rapid recovery from PRCA without any side effects was observed. We conclude that AMSC seems to be a promising therapeutic option in patients with PRCA after ABO-mismatched HSCT, in whom conventional treatment fails. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-008-0599-0Authors Baijun Fang, Henan University Henan Tumor Hospital, Henan Institute of Haematology, Henan Medical School 127 Dongming Road Zhengzhou 450008 ChinaYongping Song, Henan University Henan Tumor Hospital, Henan Institute of Haematology, Henan Medical School 127 Dongming Road Zhengzhou 450008 ChinaNing Li, Henan University Henan Tumor Hospital, Henan Institute of Haematology, Henan Medical School 127 Dongming Road Zhengzhou 450008 ChinaJing Li, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Haematology and Blood Diseases Hospital, Center of Excellence in Tissue Engineering Beijing ChinaQin Han, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Haematology and Blood Diseases Hospital, Center of Excellence in Tissue Engineering Beijing ChinaRobert Chunhua Zhao, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Haematology and Blood Diseases Hospital, Center of Excellence in Tissue Engineering Beijing China Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
The effects of air quality on haematological and clinical parameters in children with sickle cell anaemia
Thu, 04 Sep 2008 06:41:40 -0000
Abstract  Sickle cell anaemia (SCA; HbSS) is characterised by its clinical variability, which is only partly explained by known genetic factors. Environmental factors are known to contribute to acute problems but their importance in chronic complications has not been analysed. We have studied 93 children with SCA in a single institution, who underwent transcranial Doppler scanning and steady-state blood tests in 2006. These data were correlated with each individual’s exposure to pollution from dust (PM10), nitric oxide (NO) and nitrogen dioxide (NO2). This exposure was derived from patient postcodes and detailed street-level maps of average pollutant levels in 2006. All the pollutants correlated closely with each other. Increased exposure to pollution correlated with a significant reduction in total bilirubin levels, with a trend towards lower levels of lactate dehydrogenase and aspartate transaminase. There was significant correlation between extracranial internal carotid artery blood velocity and PM10 exposure. These studies suggest that chronic exposure to air pollutants could explain some variability in SCA. The lower levels of bilirubin and other markers of haemolysis with increased exposure to air pollutants could be mediated by increased exposure to NO. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-008-0598-1Authors Hrishi Mittal, King’s College London Environmental Research Group, Franklin Wilkins Building London SE1 9NH UKLara Roberts, King’s College Hospital Department of Paediatric Haematology, King’s College London School of Medicine Denmark Hill London SE5 9RS UKGary W. Fuller, King’s College London Environmental Research Group, Franklin Wilkins Building London SE1 9NH UKSandra O’Driscoll, King’s College Hospital Department of Paediatric Haematology, King’s College London School of Medicine Denmark Hill London SE5 9RS UKMoira C. Dick, King’s College Hospital Department of Paediatric Haematology, King’s College London School of Medicine Denmark Hill London SE5 9RS UKSue E. Height, King’s College Hospital Department of Paediatric Haematology, King’s College London School of Medicine Denmark Hill London SE5 9RS UKSwee Lay Thein, King’s College Hospital Department of Haematology, King’s College London School of Medicine Denmark Hill London SE5 9RS UKDavid C. Rees, King’s College Hospital Department of Paediatric Haematology, King’s College London School of Medicine Denmark Hill London SE5 9RS UK Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Non-classical hereditary hemochromatosis in Portugal: novel mutations identified in iron metabolism-related genes
Tue, 02 Sep 2008 06:07:23 -0000
Abstract  The most frequent genotype associated with Hereditary hemochromatosis is the homozygosity for C282Y, a common HFE mutation. However, other mutations in HFE, transferrin receptor 2 (TFR2), hemojuvelin (HJV) and hepcidin (HAMP) genes, have also been reported in association with this pathology. A mutational analysis of these genes was carried out in 215 Portuguese iron-overloaded individuals previously characterized as non-C282Y or non-H63D homozygous and non-compound heterozygous. The aim was to determine the influence of these genes in the development of iron overload phenotypes in our population. Regarding HFE, some known mutations were found, as S65C and E277K. In addition, three novel missense mutations (L46W, D129N and Y230F) and one nonsense mutation (Y138X) were identified. In TFR2, besides the I238M polymorphism and the rare IVS5 −9T→A mutation, a novel missense mutation was detected (F280L). Concerning HAMP, the deleterious mutation 5’UTR −25G→A was found once, associated with Juvenile Hemochromatosis. In HJV, the A310G polymorphism, the novel E275E silent alteration and the novel putative splicing mutation (IVS2 +395C→G) were identified. In conclusion, only a few number of mutations which can be linked to iron overload was found, revealing their modest contribution for the development of this phenotype in our population, and suggesting that their screening in routine diagnosis is not cost-effective. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-008-0572-yAuthors Ana Isabel Mendes, National Institute of Health Dr. Ricardo Jorge Human Genetics Centre Lisbon PortugalAna Ferro, National Institute of Health Dr. Ricardo Jorge Human Genetics Centre Lisbon PortugalRute Martins, National Institute of Health Dr. Ricardo Jorge Human Genetics Centre Lisbon PortugalIsabel Picanço, National Institute of Health Dr. Ricardo Jorge Human Genetics Centre Lisbon PortugalSusana Gomes, National Institute of Health Dr. Ricardo Jorge Human Genetics Centre Lisbon PortugalRute Cerqueira, Santa Maria da Feira Hospital Service of Gastroenterology Santa Maria da Feira PortugalManuel Correia, Santa Maria da Feira Hospital Service of Gastroenterology Santa Maria da Feira PortugalAntónio Robalo Nunes, Pulido Valente Hospital Service of Immuno-hemotherapy Lisbon PortugalJorge Esteves, S. José Hospital Unit of Gastroenterology Lisbon PortugalRita Fleming, Santa Maria Hospital Service of Immuno-hemotherapy Lisbon PortugalPaula Faustino, National Institute of Health Dr. Ricardo Jorge Human Genetics Centre Lisbon Portugal Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555

American Journal of Hematology

Consensus statement on iron overload in myelodysplastic syndromes
John M. Bennett, for the MDS Foundation's Working Group on Transfusional Iron Overload Tue, 19 Aug 2008 16:26:00 -0000
In May 2005 at the 8th International Symposium on Myelodysplastic Syndromes (MDS), a consensus meeting was held on iron overload in MDS (Seymour, Hematol Oncol Clin 2005; Suppl 1:18-25). The recommendations of the 2005 consensus meeting were discussed in the context of currently available evidence at the 9th International Symposium on Myelodysplastic Syndromes in Florence Italy, May 2007. The recommendations of the consensus working group are presented here. The recommendations are a continued refinement of the outcome of the 2005 consensus meeting and the ground-breaking work of others in this area (Seymour, Hematol Oncol Clin 2005; Suppl 1:18-25; Gattermann, Int J Hematol 2008;88:24-29; Alessandrino et al., Haematologica 2002;87:1286-1306; NCCN practice guidelines: Myelodysplastic Syndromes, version 2.2008). Am. J. Hematol., 2008. © 2008 Wiley-Liss, Inc.
Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation
Celalettin Ustun, Abhishek Kalla, Stephanie Farrow, David L. Deremer, Anand Jillella Tue, 19 Aug 2008 16:26:00 -0000
No abstract.
Prognostic relevance of anemia in myelodysplastic syndromes
Mario Cazzola, Luca Malcovati Tue, 19 Aug 2008 16:26:00 -0000
No abstract.

Pediatric Hematology and Oncology: Articles recently published in

IN VITRO HEPATIC DIFFERENTIATION OF HUMAN UMBILICAL CORD BLOOD AND BONE MARROW CELLS
Seoh, Ju-YoungWoo, So-YounCho, Kyung-ARyu, Kyung-HaJung, Yun-JaeJoo, Sun YoungYoo, KwonHo-Seoung, HanCho, Su Jin Fri, 01 Aug 2008 00:00:00 -0000

DYSPLASIA AND DISORDER OF CELL MEMBRANE ENTIRETY IN IRON-DEFICIENCY ANEMIA
Çetinkaya, Duygu UçkanOlcay, LaleElmas, Selin AytaçKuşkonmaz, BarışUnal, SuleAslan, DenizYetgin, SevgiTavil, Betül Fri, 01 Aug 2008 00:00:00 -0000

SENSORY NEURAL HEARING LOSS IN β-THALASSEMIA MAJOR PATIENTS TREATED WITH DEFEROXAMINE
Amini, ReyhanehGarallahi, FarnoushEsfehani, HosseinAlavi, SaminArzanian, M. TaghiMoghadassian, HabiballahAminasnafi, AliShamsian, Bibi ShahinGachkar, Latif Fri, 01 Aug 2008 00:00:00 -0000


Subscribe to Hematology RSS feed